エピソード

  • The Question Behind the Question - Field Training with Jennifer Muszik

    The Question Behind the Question - Field Training with Jennifer Muszik
    2026/06/08

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question — the real need behind what a customer is asking.

    In this episode, Jonathan Kaskey sits down with Jennifer Muszik, Head of Learning & Development at Alkermes and board member of LTEN, to unpack what it takes to build world-class training programs in the pharmaceutical industry. Jennifer shares her journey from 17 years at Pfizer to leading L&D across some of pharma's most recognized organizations — and why she almost always hires people who've actually done the job they're training others to do.

    They get into the nuances of training new hires vs. seasoned veterans, how to engage your highest performers without making them feel attacked, and why former teachers and coaches often make the best pharma reps. Plus: a candid conversation about where AI can genuinely help — and where human connection is still irreplaceable.

    Topics covered:

    • Why field experience makes better trainers
    • The "pull-through" problem after POA meetings
    • Using AI for knowledge transfer (and its limits)
    • How LTEN is shaping the future of pharma L&D

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    29 分
  • Why the Small Details Reveal Everything About Your CDMO Partner with Frank Sorce

    Why the Small Details Reveal Everything About Your CDMO Partner with Frank Sorce
    2026/05/28

    In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Frank Sorce, Chief Commercial Officer at UPM Pharmaceuticals, to share insights into the critical decisions involved in selecting contract development and manufacturing organizations (CDMOs).

    Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.

    The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.

    Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com


    Episode Resources:

    • Frank Sorce on LinkedIn
    • UPM Pharmaceuticals Website
    • Jonathan Kaskey on LinkedIn
    • XSUNT Corporation Website

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    30 分
  • Why Medical Knowledge Isn’t Reaching Patients with Dr. Simon Chowdhury

    Why Medical Knowledge Isn’t Reaching Patients with Dr. Simon Chowdhury
    2026/05/21

    In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Dr. Simon Chowdhury, a Consultant Medical Oncologist based at Guy's and St Thomas' NHS Foundation Trust, to talk about Open Medicine, a platform designed to take what’s inside the minds of the world’s leading oncologists and make it accessible to any clinician on a mobile phone.

    Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.

    The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.

    Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    37 分
  • Timothy Smith on AI, Data, and Drug Discovery at Takeda

    Timothy Smith on AI, Data, and Drug Discovery at Takeda
    2026/05/14
    In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Timothy Smith, Senior Director of AI Innovation and Head of the Data Sciences Communities at Takeda, to explore how AI is transforming drug discovery and development, why trust and governance are still major hurdles, and why the biggest bottleneck in pharma innovation might not be technology but people. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations. Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    33 分
  • Lessons on Leading Through Uncertainty in Pharma

    Lessons on Leading Through Uncertainty in Pharma
    2026/05/07
    In this episode of Pharma Sessions, host Jonathan Kaskey welcomes back Danie du Plessis, the first-ever guest on Pharma Sessions, for a wide-ranging conversation about what it takes to lead in medical affairs today. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations. Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    36 分
  • Where AI Delivers Real Value in Pharma Today with Emily Lewis

    Where AI Delivers Real Value in Pharma Today with Emily Lewis
    2026/04/30
    Here’s what keeps pharma leaders awake at night: 70% to 80% of ChatGPT usage is healthcare-related; however, most pharmaceutical organizations still treat AI as a future consideration rather than an immediate competitive necessity. In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Emily Lewis, Artificial Intelligence and Innovation Lead for Digital Care Transformation at UCB, to explore why LLMs alone won’t move medicine forward, how to build cross-functional AI literacy across your organization, and the regulatory workflows where AI will deliver impact fastest. Disclaimer: Pharma Sessions is for informational purposes only and does not constitute medical, legal, or financial advice. Guest opinions are their own and do not reflect the views of the host or sponsors. Use of any information provided is at the listener’s own risk and does not imply endorsement of specific products or strategies.

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    33 分
  • How Medical Affairs Becomes the Connector with Sonia Talwar

    How Medical Affairs Becomes the Connector with Sonia Talwar
    2026/04/23
    In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Sonia Talwar, Senior Director of Scientific Communications and Medical Information in Hematology/Oncology at Pharmacosmos Therapeutics, to discuss how medical affairs can evolve from a reactive support function into a true strategic connector. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations. Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    26 分
  • Why Manufacturing Is the New Competitive Edge in Cell and Gene Therapy

    Why Manufacturing Is the New Competitive Edge in Cell and Gene Therapy
    2026/04/16
    In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Eytan Abraham, the Chief Commercial and Technology Officer at Minaris Advanced Therapies, to dive into how pharma companies can choose the right CDMO partners, the future of cell and gene therapy manufacturing, and the hard-earned lessons behind building sustainable, high-performance organizations in one of the most complex areas of medicine. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations. Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.

    Pharma Sessions is hosted by Jonathan Kaskey

    Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

    Or join the Pharma Sessions Substack:
    www.pharmasessions.substack.com
    続きを読む 一部表示
    33 分